September 11, 2018: The AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. Required by Congress in 2010, HHS has delayed the rule’s effective date five times. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers.
For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
The AHA is pleased that, in response to our successful lawsuit, the Health Resources and Services Administration today launched a new website to shine needed…
Bipartisan Legislation Would Increase the Number of Medicare-funded Residency Positions and Help Alleviate Physician Shortages
Bipartisan bills were recently introduced in both chambers of Congress to help alleviate the critical shortage of physicians.
Following a December 17, 2018 status conference, the Court issued a minute order requiring defendants to "file [a] status report pertaining to their progress…
Opposition to Government’s Motion to Dismiss and Reply in Support of Motion for a Permanent Injunction Covering the 2019 OPPS Rule
In a highly unusual filing, Defendants seek to defend the 2019 OPPS Rule with arguments that Defendants forthrightly acknowledge the Court has already rejected…